NeuroDerm Ltd. Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
6/19/2013 10:34:35 AM
More...
|
NeuroDerm Ltd. Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
6/13/2013 6:37:07 AM
More...
|
NeuroDerm Ltd. Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson's Disease
6/3/2013 10:54:32 AM
More...
|
NeuroDerm Ltd. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York City
5/31/2013 9:40:20 AM
More...
|
NeuroDerm Ltd. Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
4/15/2013 10:10:03 AM
More...
|
NeuroDerm Ltd. Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinson's Disease
3/4/2013 9:43:19 AM
More...
|
NeuroDerm Ltd. Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinson's Disease
11/9/2011 6:44:49 AM
More...
|
NeuroDerm Ltd. Raises $2.5 Million in Series A Financing
7/23/2007 11:35:01 AM
More...
|